作者: Steven M. Keller , Sudeshna Adak , Henry Wagner , Arnold Herskovic , Ritsuko Komaki
DOI: 10.1056/NEJM200010263431703
关键词:
摘要: Background We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior alone in prolonging survival and preventing local recurrence patients with completely resected stage II or IIIa non–small-cell lung cancer. Methods After surgical staging resection of the tumor (usually by lobectomy pneumonectomy), were randomly assigned receive either four 28-day cycles cisplatin (60 mg per square meter body-surface area intravenously on day 1) etoposide (120 days 1, 2, 3) administered concurrently (a total 50.4 Gy, given 28 daily fractions) fractions). Results Of 488 who enrolled study, 242 246 radiotherapy. The median duration follow-up was 44 months. Treatment...